The fabrication of magnetic particle-based chemiluminescence immunoassay for human epididymis protein-4 detection in ovarian cancer

The magnetic particles have a significant influence on the immunoassay detection and cancer therapy. Herein, the chemiluminescence immunoassay combined with the magnetic particles (MPCLIA) was presented for the clinical determination and analysis of human epididymis protein 4 (HE4) in the human serum. Under the optimized experiment conditions, the secure MPCLIA method can detect HE4 in the broader range of 0–1000 pmol/L, with a lower detection limit of 1.35 pmol/L. The satisfactory recovery rate of the method in the serum ranged from 83.62% to 105.10%, which was well within the requirement of clinical analysis. Moreover, the results showed the good correlation with enzyme-linked immunosorbent assay (ELISA), with the correlation coefficient of 0.9589. This proposed method has been successfully applied to the clinical determination of HE4 in the human serum.

[1]  Xiaojie Song,et al.  Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis , 2017, Open medicine.

[2]  Hong-yan Cheng,et al.  Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma , 2011, International Journal of Gynecologic Cancer.

[3]  Xiaolin Fu,et al.  Chemiluminescence enzyme immunoassay using magnetic nanoparticles for detection of neuron specific enolase in human serum. , 2012, Analytica chimica acta.

[4]  M. Panteghini,et al.  Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review , 2013, Journal of Clinical Pathology.

[5]  Y. Wan,et al.  Preparation of an Acridinium Ester-Labeled Antibody and Its Application in GoldMag Nanoparticle-Based, Ultrasensitive Chemiluminescence Immunoassay for the Detection of Human Epididymis Protein 4 , 2017, Micromachines.

[6]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[7]  R. Angioli,et al.  The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review , 2017, Expert review of anticancer therapy.

[8]  Gary Goodman,et al.  Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study , 2010, Journal of the National Cancer Institute.

[9]  W. Guo,et al.  A sandwich electrochemiluminescence immunosensor for highly sensitive detection of alpha fetal protein based on MoS2-PEI-Au nanocomposites and Au@BSA core/shell nanoparticles , 2017 .

[10]  Li Zhang,et al.  Magnetic microbead-based enzyme-linked immunoassay for detection of Schistosoma japonicum antibody in human serum. , 2010, Analytical biochemistry.

[11]  A. Salimi,et al.  An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing. , 2017, Biosensors & bioelectronics.

[12]  R. Kučera,et al.  Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management. , 2017, Anticancer research.

[13]  M. Speeckaert,et al.  Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. , 2013, Advances in clinical chemistry.

[14]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[15]  Rong-Liang Liang,et al.  Rapid quantitation of human epididymis protein 4 in human serum by amplified luminescent proximity homogeneous immunoassay (AlphaLISA). , 2016, Journal of immunological methods.

[16]  Wei-Wen Xu,et al.  The Establishment of an HE4‐CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer , 2016, Journal of clinical laboratory analysis.